Mr. Paul Levesque reports

THERATECHNOLOGIES REPORTS ON ITS ANNUAL MEETING OF SHAREHOLDERS

Theratechnologies Inc. has released the voting results from its annual meeting of shareholders held today in a virtual-only setting.

As part of the meeting, Paul Levesque, president and chief executive officer of Theratechnologies, confirmed that the amended protocol for the phase 1 clinical trial studying the company's lead oncology asset, sudocetaxel zendusortide (TH1902), has been filed with the U.S. Food and Drug Administration (FDA). He also stated that once the proposed changes are approved by the FDA, the company plans to hold a conference call with analysts and investors to provide insights on the updated clinical trial protocol.

Shareholders proceeded to elect candidates to the company's board of directors for a one-year term and appointed KPMG LLP as the company's auditor for the current fiscal year. Shareholders also passed resolution 2023-1, approving amendments to the company's share option plan. All candidates proposed for the position of director were elected.

              VOTING RESULTS FOR ELECTION OF DIRECTORS

                           For   % for     Abstention   % abstention 

Joseph Arena        23,138,582   73.03%     8,545,048          26.97%    
Frank Holler        23,065,196   72,80%     8,618,434          27.20%    
Gerald A. Lacoste   18,403,644   58.09%    13,279,986          41.91%    
Paul Levesque       23,077,346   72.84%     8,606,284          27.16%    
Gary Littlejohn     18,569,960   58.61%    13,113,670          41.39%    
Andrew Molson       22,847,163   72.11%     8,836,467          27.89%    
Dawn Svoronos       22,723,149   71.72%     8,960,481          28.28%    
Alain Trudeau       21,945,983   71.72%     9,737,647          28.28%    
Dale Weil           22,847,453   72.11%     8,836,177          27.89%    

About Theratechnologies Inc.

Theratechnologies (Toronto Stock Exchange: TH) (Nasdaq: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.